Introduction The transformation of pharmaceuticals into financial assets has introduced the logics of scarcity and high prices from low-to-middle income countries to high-income countries. This shift has spurred new forms of activism, raising the question: will similar patterns emerge with the assetization of medical data and medical AI? This article